Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study

Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2014, Pages 168-178

  Padhi, Desmond ^a   Allison, Mark ^b   Kivitz, Alan J ^c   Gutierrez, Maria J ^d   Stouch, Brian ^a   Wang, Christine ^a   Jang, Graham ^a  

^a AMGEN INC   (United States)

^b MDS Inc   (Canada)

^c Altoona Center for Clinical Research   (United States)

^d Comprehensive Phase One ^*  (United States)

Author keywords

AMG 785; Bone mineral density; CDP7851; Pharmacodynamics; Pharmacokinetics; Romosozumab; Sclerostin

Indexed keywords

CALCIUM ION; CARBOXY TERMINAL TELOPEPTIDE; NEUTRALIZING ANTIBODY; PLACEBO; ROMOSOZUMAB; TYPE 1 AMINOTERMINAL PROPEPTIDE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; MONOCLONAL ANTIBODY; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE MASS; CALCIUM BONE LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; LIMB PAIN; LUMBAR SPINE; LYMPHADENOPATHY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NORMAL HUMAN; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; LUMBAR VERTEBRA; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

EID: 84894866129     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.239     Document Type: Article

References (18)

1. National Osteoporosis Foundation. Prevalence Report. Available at: (http://www.nof.org/advocacy/resources/prevalencereport) Accessed 11 August 2012.
2. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res. 2010;25(9):1897-1904.
3. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577-589.
4. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537-543.
5. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860-869.
6. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-588.
7. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25(5):948-959.
8. Baron R, Rawadi G., Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635-2643.
9. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20): 19883-19887.
10. Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006;21(11):1738-1749.
11. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19-26.
12. Bachmann G, Kriegman A, Goncalves J, Kianifard F, Warren M, Simon JA. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density. Menopause. 2011;18(8):851-856.
13. Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab. 2008;93(7): 2463-2465.
14. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25-54; quiz 55-26.
15. Watts NB, Bilezikian JP, Camacho PM, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(Suppl. 3):1-37.
16. Shiraki M, Sugimoto T, Nakamura T. Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women. Osteoporos Int. 2013;24(1):219-226.
17. FORTEOTM (teriparatide [rDNA origin] injection) prescribing information. Indianapolis, IN: Eli Lilly and Company; 2012.
18. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165(15):1762-1768.